Sistemik skleroz: Neden ve nasıl?

Year 2013, Volume: 30 Issue: 1s, 39 - 45, 28.11.2013

Ali Şahin , Mehmet Pepeler

Abstract

Sistemik skleroz (SSk), cilt ve akciğer, kalp, böbrek ve gastrointestinal sistem gibi birçok organ ve sistemi tutabilen etiyolojisi hala bilinmeyen bir otoimmün hastalıktır. SSk’un patogenezinde; inflamasyon, mikrovasküler yapı ve immün sistemde bir dizi değişiklik, aşırı ektrasellüler matriks üretimi sorumludur. İşte bu immün sistemdeki kompleks etkileşimler sonucunda gelişen cilt ve iç organlardaki fibrozis, hastalığın klinik tablosunu oluşturur. Hastalardaki bu klinik farklılığı neyin oluşturduğu ise tam olarak bilinmemektedir. Klinik bulguların çeşitliliği SSk tedavisinin diğer romatizmal hastalıklardan daha zor ve bireysel olmasına yol açmaktadır. Fakat bu derlemede SSk tutulum özellikleri ve tedavisinden ziyade nedenleri güncel bilgiler ışığında anlatılmaya
çalışılmıştır.

Keywords

Fibrozis, İnflamasyon, Lenfosit, Otoimmünite, Sistemik skleroz, Vaskülopati

References

• Aoyagi-Ikeda, K., Maeono, T., Matsui, H., Ueno, M., Hara, K., Aoki, Y., Aoki, F., Shimizu, T., Doi, H., Kawai-Kowase, K., Iso, T., Suga, T., Arai, M., Kurabayashi, M., 2011. Notch induces myofibroblast differentiation of alveolar epithelial cells via transforming growth factor-(beta)Smad3 pathway. Am. J. Respir. Cell Mol. Biol. 45, 136-144.
• Arnett, F.C., Cho, M., Chatterjee, S., Aguilar, M.B., Reveille, J.D., Mayes, M.D., 2001. Familial occurence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 44, 1359-1362.
• Artlett, C.M., 2002. Microchimerism in health and disease. Curr. Mol. Med. 2, 525-535.
• Artlett, C.M., Cox, L.A., Ramos, R.C., Dennis, T.N., Fortunato, R.A., Hummers, L.K., Jimenez, S.A., Smith, J.B., 2002. Increased microchimeric CD4+ T lymphocytes in peripheral blood from women with systemic sclerosis. Clin. Immunol. 103, 303-308.
• Artlett, C.M., 2005. Immunology of systemic sclerosis. Front. Biosci. 10, 1707-1719.
• Assassi, S., Arnett, F.C., Reveille, J.D., Gourh, P., Mayes, M.D., 2007. Clinical,immunologic, and genetic features of familial systemic sclerosis. Arthritis Rheum. 56, 2031-2037.
• Bianchi, D.W., Zickwolf, G.K., Weil, G.J., Sylvester, S., DeMaria, M.A., 1996. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc. Natl. Acad. Sci. USA. 93, 705-708.
• Cadavid, A., Rugeles, M.T., Pena, B., Sanchez, F., Garcia, H., Garcia, G., Botero, J., Castaneda, Ossa, J., 1997. Cell microchimerism in patients with recurrent spontaneous abortion: Preliminary results. Early Pregnancy. 3, 199-203.
• Chifflot, H., Fautzi, B., Sordet, C., Chatelus, E., Sibila, J., 2008. Incidence and prevalence of systemic sclerosis: A systematic lierature review. Semin. Arthritis Rheum. 37, 223-235.
• Chizzolini, C., 2008. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr. Opin. Rheumatol. 20, 707-712.
• Demir, C., Sahin, A., Turkcapar, N., Kucuksahin, O., Turgay, M., 2011. The Importance of Interleukin-23 and Interleukin-17 in the Patients with Systemic Sclerosis. RAED journal. 3, 14-15.
• Earnshaw, W., Bordwell, B., Marino, C., Rothfield, N., 1986. Three human chromosomal autoantigens are recognised by sera from patients with anticentromer antibodies. J. Clin. Invest. 77, 426-430.
• Feghali-Bostwick, C.A., Medsger, T.A., Wright, T.M., 2003. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of anti-nuclear antibodies. Arthritis Rheum. 48, 1956-1963.
• Gabrielli, A., Avvedimento, E.V., Krieg, T., 2009. Scleroderma (mechanisms of disease). N. Engl. J. Med. 360, 1989-2003.
• Giacomelli, R., Cipriani, P., Fulminis, A., Nelson, J.L., Matucci-Cerinic, M, 2004. Gamma/delta T cells in placenta and skin: Their different functions may support the paradigm of microchimerism in systemic sclerosis. Clin. Exp. Rheumatol. 22, 528-530.
• Grossman, C., Dovrish, Z., Shoenfeld, Y., Amital, H., 2010. Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev. doi: 1016/j.autrev.
• Gu, Y.S., Kong, J., Cheema, G.S., Keen, C.L., Wick, G., Gershwin, M.E., 2008. The immunobiology of systemic sclerosis. Semin. Arthritis Rheum. 38, 132-160.
• Hertzman, P.A., Blevins, W.L., Mayer, J., Greenfield, B., Ting, M., Gleich, G.J., 1990. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N. Engl. J. Med. 322, 869-873.
• Hinchcliff, M., Varga, J., 2008. Systemic sclerosis/Scleroderma: A Treatable Multisystem Disease. Am. Fam. Physician. 78, 961-969.
• Hirakata, M., Okano, Y., Pati, U., Suwa, A., Medsger, T.A., Jr. Hardin, J.A., Craft, J., 1993. Identification of auotantibodies to RNA polymerase II: Occurence in systemic sclerosis and association with autoantibodies to RNA polymerase I and III. J. Clin. Invest. 91, 2665-2672.
• Hudson, L.L., Silver, R.M., Pandey, J.P., 2004. Ethnic differences in cytotoxic T lymphocyte associated antigen 4 genotype associations with systemic sclerosis. J. Rheumatol. 31, 85-87.
• Ihn, H., Yamane, K., Kubo, M., Tamaki, K., 2001. Blockade of endogenous transforming growth factor β signaling prevents upregulated collagen synthesis in scleroderma fibroblasts: Association with increased expresion of transforming growth factor β receptors. Arthritis Rheum. 44, 474-4
• Jimenez, S.A., Artlett, C.M., 2005. Microchimerism and systemic sclerosis. Curr. Opin. Rheumatol. 17, 86-90.
• Kahaleh, M.B., LeRoy, E.C., 1989. Interleukin-2 in scleroderma: Correlation of serum level with extent of skin involvement and disease duration. Ann. Intern. Med. 10, 446-450.
• Kratz, L.E., Broughman, J.A., Pincus, T., Cohen, D.I., Needleman, B.W., 1990. Association of scleroderma with a T cell antigen receptor gene resctriction fragment length polymorphism. Arthritis Rheum. 33, 569-573.
• Kuwana, M., Medsger, T.A., Jr., Wright, T.M., 1995. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J. Immunol. 155, 2703-2714.
• Lambert, N.C., Lo, Y.M., Erickson, T.D., Tylee, T.S., Guthrie, K.A., Furst, D.E., Nelson, J.L., 2002. Male microchimerism in healthy women and women with scleroderma: Cells or circulating DNA? A quantitative answer. Blood. 100, 2845-2851.
• Lee, E.S.M., Bou-Gharios, G., Seppanen, E., Khosrotehrani, K., Fisk, N.M., 2010. Fetal stem cell microchimerism: natural-born healers or killers? Mol. Hum. Rep. 16, 869-878.
• LeRoy, E.C., Black, C., Fleishmajer, R., Jablonska, S., Krieg, T., Medsger, T.A, Jr., Rowell, N., Wollheim, F., 1988. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J. Rheumatol. 15, 202-205.
• LeRoy, E.C., Medsger T.A, Jr., 2001. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573-1576.
• çe artan “hedefe yönelik” tedaviler, bu “komlpkes-heterojen hastalığın” tabiatı gereği çok yüz güldürücü olmasa da çalışmalar devam etmektedir. Bugün için “neden ve nasıl”ı henüz tam olarak açıklanamayan SSk hastalarında iş gücü kaybı, yaşam kalitesi ve beden imgesinde bozulma, ileri dönemlerde eşlik edebilen depresyon gibi faktörlerden dolayı gelişen bu kısır döngü tedavi maliyetlerini de etkilemektedir.